Association between the ENPP1 K121Q Polymorphism and Risk of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis

Denise Alves Sortica¹,², Marjorie Piucco Buffon¹,², Bianca Marmontel Souza¹,², Bruna Bellicanta Nicoletto¹,², Andressa Santer¹, Tais Silveira Assmann¹,², Daisy Crispim¹,², Luis Henrique Canani¹,²*

¹ Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil, ² Postgraduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

* luishenriquecanani@gmail.com

Abstract

The potential association between the K121Q (A/C, rs1044498) polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) gene and risk of diabetic kidney disease (DKD) has been investigated. Nevertheless, the effect of this variant on DKD risk is still under debate, and conflicting results have been reported. To this date, no meta-analysis has evaluated the association of the K121Q polymorphism with DKD. This paper describes the first meta-analysis conducted to evaluate whether the ENPP1K121Q polymorphism is associated with DKD. A literature search was conducted to identify all case-control or cross-sectional studies that evaluated associations between the ENPP1K121Q polymorphism and DKD. Pooled odds ratios (OR) and 95% confidence intervals (95% CI) were calculated for allele contrast, additive, dominant and recessive inheritance models. Seven studies were eligible for inclusion in the meta-analysis, providing data on 3571 type 1 or type 2 diabetic patients (1606 cases with DKD and 1965 diabetic controls without this complication). No significant heterogeneity was observed among the studies included in the meta-analysis when assuming different inheritance models (I² < 50% or P > 0.10 for the entire sample and after stratification by ethnicity). Meta-analysis results revealed significant associations between the K121Q polymorphism and increased susceptibility of DKD in European and Asian populations.
Introduction

The number of people living with diabetes mellitus (DM) worldwide is expected to double between 2000 and 2030 [1,2]. This global increase in the prevalence of DM will lead to a higher incidence of the chronic complications of diabetes [3]. Diabetic kidney disease (DKD) is a common diabetic chronic complication [4]. DKD is characterized by albuminuria and reduced glomerular filtration rate (GFR) [4]. Approximately 40% of patients with diabetes, whether type 1 or type 2, develop some degree of renal disease after many years of DM [5]. DKD is thus the most common cause of end-stage renal disease in several countries, and it is associated with high morbidity and mortality rates among diabetic patients [6,7].

The mechanisms involved in the pathogenesis of DKD are multiple and complex. Both epidemiological and familial studies have shown major agreement for clustering of DKD in some families, strengthening the hypothesis that there are important genetic factors involved in its pathogenesis [7]. Environmental factors such as hyperglycemia, arterial hypertension and/or dyslipidemia are known to play a key role in the development of DKD in genetically susceptible subjects [5,6,8,9]. Therefore, extensive efforts have been made to identify which genes are related to DKD; however, results are still inconclusive due to several genes being associated with small effects in different populations [10,11,12,13]. The identification of such genes will help detect individuals at high risk of developing DKD, and might provide a better understanding of its pathophysiology [14].

Candidate genes for insulin resistance (IR) can also be considered as DKD candidate genes in patients with type 1 or type 2 DM [15]. In this context, the gene that encodes the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) is a good candidate gene for DKD [12,16]. The ENPP1 gene is expressed in many tissues, including the kidneys, and it is known that increased ENPP1 gene expression blockades the tyrosine kinase activity of the insulin receptor in several cells, causing IR [7]. More than 15 years ago, a polymorphism was reported in exon 4 of this gene leading to a lysine (K) to glutamine (Q) substitution in codon 121 (K121Q; rs1044498) [7,12]. This change is located in one of the ENPP1 somatomedin-B-like domain, and might influence protein-protein interactions [7,17]. Furthermore, the Q allele of the K121Q variant has been shown to influence ENPP1 protein function by inhibiting insulin receptor function and insulin signaling more effectively than the K allele [12].

Since then, several studies have investigated the association between the K121Q polymorphism and IR, type 2 DM (T2DM) and/or its chronic complications, such as DKD (for a review, see [7]). However, the impact of this polymorphism on DKD susceptibility is still under debate, with contradictory findings: while some studies reported an association of the Q allele with DKD [18,19,20,21], other studies were not able to replicate this association [22,23].

Thus, to further investigate the potential association of the ENPP1 K121Q polymorphisms with DKD, we conducted a systematic review and meta-analysis of the literature on the subject.

Materials and Methods

Search strategy and eligibility criteria

This study was designed and reported in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), Meta-analysis of Observational Studies in Epidemiology (MOOSE) statements, and following the Meta-analysis on Genetic Association Studies Checklist from Plos One (S1 Table) [24,25].

PubMed and Embase databases were searched systematically to identify all genetic studies that investigated associations between DKD and the K121Q polymorphism. The K121Q polymorphism was selected for the present meta-analysis because it has been the most frequently
studied polymorphism in ENPP1 gene. There are not enough data concerning the other ENPP1 polymorphisms and diabetic kidney disease to perform a meta-analysis. The following medical subject headings (MeSH) were used: (“Phosphodiesterase I”[7] OR “ectonucleotide pyrophosphatase phosphodiesterase I”[Supplementary Concept]) AND (“Polymorphism, Genetic”[-Mesh] OR “Polymorphism, Single Nucleotide”[Mesh] OR “Polymorphism, Restriction Fragment Length”[Mesh] OR “Amplified Fragment Length Polymorphism Analysis”[Mesh] OR “Polymorphism, Single-Stranded Conformational”[Mesh] OR “DNA Copy Number Variations”[Mesh] OR “Mutation”[Mesh] OR “Mutation, Missense”[Mesh] OR “INDEL Mutation”[-Mesh] OR “Point Mutation”[Mesh] OR “Frameshift Mutation”[Mesh] OR “Codon, Nonsense”[Mesh]) AND (“Diabetes Mellitus”[Mesh] OR “Diabetes Complications”[Mesh] OR “Diabetes Mellitus, Type 2”[Mesh] OR “Diabetes Mellitus, Type 1”[Mesh]). The search was restricted to papers reporting on human subjects and published in English or Spanish, and was completed on July 25th, 2014. It is worth noting that although we aimed to analyze only studies published in English or Spanish, we did not identify any study in another language which analyzed the K121Q polymorphism and diabetic kidney disease. All of the papers found were also searched manually to identify other relevant citations. Moreover, unpublished results were searched in the abstract books of the Endocrine Society, American Diabetes Association, and European Association for the Study of Diabetes (EASD) Meetings.

Eligibility was evaluated through a review of titles and abstracts; when abstracts did not provide sufficient information, the full text of the paper was retrieved for analysis, as in previous reviews by our group [26,27,28]. Briefly, this was done independently in a standardized manner by two investigators (D.A.S and M.P.B.). Disagreements were resolved by discussion between them and, if required, a third reviewer (D.C.) was consulted. We included observational studies that evaluated the frequencies of the K121Q polymorphism in patients with DKD (cases) and diabetic patients without any degree of DKD (controls). Both type 1 and type 2 diabetic patients older than 18 years were included. Studies would be excluded from analysis if the genotype distributions in the control group deviated from those predicted by Hardy-Weinberg equilibrium (HWE) or if they did not provide sufficient data to estimate an odds ratio (OR) with 95% CI. However, no study was excluded due to these criteria. If results were duplicated and had been published more than once, the most complete article was included in the study.

Data extraction

Necessary information from each study was extracted by two investigators working independently (D.A.S and M.P.B.), using a standardized extraction form, and consensus was sought for all extracted items. When consensus could not be achieved, differences in data extraction were decided by reading the original publication [26,27,28]. The data extracted from each study were as follows: (1) characteristics of the study (including name of the first author, year of publication, number of subjects included in the case and control groups) and sample characteristics, such as age, gender, ethnicity, type of DM, DM duration, HbA1c, body mass index (BMI), systolic and diastolic blood pressure, percentage of hypertension, lipid profile, DKD classification and information regarding kidney function; (2) case and control definitions; (3) polymorphism frequencies (including genotype and allele distributions in case and control groups and ORs with 95% CIs). When data were not available, the authors were contacted by email.

Quality control assessment

Two investigators (D.A.S and D.C.) independently evaluated the quality of each eligible article using the Newcastle-Ottawa Scale (NOS) for observational studies [29]. The NOS contains
nine items subdivided into three dimensions, including selection, comparability, and exposure. For each item, a sequence of answer alternatives is provided. A star scoring system is used for semi-quantitative evaluation of article quality, such that the highest-quality studies are assigned a maximum of one star for each item, with the exception of the comparability item, which can be assigned two stars. Therefore, the total NOS score ranges from zero to nine stars.

Statistical analysis

Control subjects’ genotype frequencies were tested for compliance with HWE using a goodness-of-fit chi-square ($\chi^2$) test. Gene-disease associations were measured using OR (95% CI) estimations based on the following genetic inheritance models: 1) allele contrast; 2) additive model; 3) recessive model; 4) and dominant model \[30\]. Taking into account that the frequency of the ENPP1 K121Q polymorphism varies across different populations, gene-disease associations for the different inheritance models were also analyzed according to ethnicity.

Heterogeneity was evaluated using a $\chi^2$-based Cochran’s Q statistic and inconsistency was tested by the I$^2$ metric. Heterogeneity would be considered statistically significant at $P < 0.10$ for the Q statistic or $I^2 > 50\%$ for the $\Gamma^2$ metric statistic \[29, 30\]. However, since no significant heterogeneity was detected, the fixed effect model (FEM) was used to calculate OR (95% CI) for each individual study and for the pooled effect \[31\]. Due to the lack of inter-study heterogeneity, we did not perform meta-regression analyses (adjusting for covariables such as age, sex, body mass index or environmental factors) or sensitivity analysis. All statistical analyses were performed using Stata 11.0 software (StataCorp, College Station, TX, USA).

Results

Our search strategy yielded 115 possibly relevant papers (Fig. 1), 103 of which were excluded following the review of titles and abstracts. Twelve articles appeared eligible after this phase and were selected for full-text evaluation. Nevertheless, after cautious reading of the full texts, further studies were excluded owing to missing information, ineligible study design or because the ENPP1 polymorphism reported was not the one of interest for this meta-analysis. Therefore, seven articles fulfilled the eligibility criteria and were included in the meta-analysis, providing data on 3571 subjects (1606 cases with DKD and 1965 diabetic controls without this complication). The study reported by Leitão et al. \[10\] was subdivided into two studies because it analyzed the ENPP1 polymorphism in two different populations.

S2 Table depicts the main characteristics of the studies included in our meta-analysis. Regarding the DKD classification, Canani et al. \[18\] subdivided cases into two groups, proteinuric and end-stage renal disease (ESRD), while Leitão et al. \[10\] and De Cosmo et al. \[20\] defined DKD patients as microalbuminuric or macroalbuminuric. Wu et al. \[19\], Lin et al. \[21\] and Tarnow et al. \[32\] classified all DKD cases as macroalbuminuric. S3 Table lists genotype and allele distributions and ORs (95% CI) for the ENPP1 K121Q polymorphism in case and control groups from the five articles reviewed.

A quality evaluation of each individual study included in the meta-analysis is shown in Table 1. The highest-quality papers were awarded nine stars. Overall, most studies were classified as having at least moderate quality in terms of selection, comparability and exposure criteria. Wu et al. \[19\] was awarded eight stars; Lin et al. \[21\], Canani et al. \[18\] and De Cosmo et al. \[20\] were awarded seven stars; Tarnow et al. \[32\], six stars; and Leitão et al. \[10\], five stars.

Table 2 summarizes the results of the pooled meta-analyses for associations between the ENPP1 K121Q polymorphism and risk of DKD. In general, our results revealed significant associations between the K121Q polymorphism and risk of DKD when assuming allele contrast, additive, recessive and dominant inheritance models. Notably, the most powerful association
was observed for the additive model (OR = 1.74, 95% CI 1.27–2.38). Moreover, after stratification by ethnicity, the associations between the K121Q polymorphism and risk of DKD remained in Europeans and Asians (Table 2 and Fig. 2). There was only one study performed in Africans [10], which showed that the K121Q polymorphism was not associated with DKD in this population.
No significant heterogeneity was observed among the analyzed studies investigating the ENPP1 K121Q polymorphism when assuming different inheritance models ($I^2 < 50\%$ or $P > 0.10$ for the entire sample and also after stratification by ethnicity; Table 2).

**Discussion**

The effect of the ENPP1 K121Q polymorphism on susceptibility to DKD is still controversial: while some studies reported an association of the Q allele with DKD risk [18,19,20,21,33], other studies were not able to replicate this association [22,23], possibly due to small sample sizes and differences in K121Q frequencies among ethnicities. Therefore, to further evaluate whether this polymorphism is associated with DKD risk, we conducted a meta-analysis of five

### Table 1. Newcastle-Ottawa quality assessment scores for the studies included in the meta-analysis.

| Author              | Year | Selection | Comparability | Exposure |
|---------------------|------|-----------|---------------|----------|
| Tarnow et al. [32]  | 2001 | **        | **            | **       |
| Canani et al. [18]  | 2002 | ***       | *             | ***      |
| Leitão et al. [10]  | 2008 | **        | ***           | **       |
| De Cosmo et al. [20] | 2009 | ***       | **            | **       |
| Wu et al. [19]      | 2009 | ***       | **            | ***      |
| Lin et al. [21]     | 2011 | **        | **            | ***      |

doi:10.1371/journal.pone.0118416.t001

### Table 2. Pooled measures for association between the ENPP1 K121Q polymorphism and susceptibility to diabetic kidney disease.

| Inheritance model | No. of studies | No. of cases | $I^2$ (%) | Pooled OR (95% CI) |
|-------------------|----------------|--------------|-----------|-------------------|
| **Allele contrast** |                |              |           |                   |
| Overall*          | 7              | 1,606        | 41.0      | 1.36 (1.20–1.53)  |
| European          | 4              | 1,102        | 17.9      | 1.28 (1.11–1.49)  |
| Asian             | 2              | 431          | 0.0       | 1.72 (1.35–2.18)  |
| **Additive**      |                |              |           |                   |
| Overall*          | 7              | 1,606        | 10.5      | 1.74 (1.27–2.38)  |
| European          | 4              | 1,102        | 30.4      | 1.79 (1.16–2.76)  |
| Asian             | 2              | 431          | 0.0       | 2.15 (1.23–3.75)  |
| **Recessive**     |                |              |           |                   |
| Overall*          | 7              | 1,606        | 5.5       | 1.54 (1.15–2.08)  |
| European          | 4              | 1,102        | 31.8      | 1.71 (1.11–2.62)  |
| Asian             | 2              | 431          | 0.0       | 1.75 (1.01–3.02)  |
| **Dominant**      |                |              |           |                   |
| Overall*          | 7              | 1,606        | 43.7      | 1.40 (1.21–1.62)  |
| European          | 4              | 1,102        | 27.2      | 1.28 (1.08–1.52)  |
| Asian             | 2              | 431          | 0.0       | 1.91 (1.43–2.55)  |

No significant heterogeneity was observed among the analyzed studies investigating the ENPP1 K121Q polymorphism when assuming different inheritance models. Thus, fixed effect models (FEM) were used for the calculation of OR (95% CI) for each individual study and for the pooled effect.

* Studies included: 4 with patients of European descent; 2 with patients of Asian descent; 1 with patients of African descent.

doi:10.1371/journal.pone.0118416.t002
studies carried out in different populations. Our results revealed significant associations between the K121Q polymorphism and risk of DKD in all genetic inheritance models analyzed.

As already mentioned, increased ENPP1 levels blockade the tyrosine kinase activity of the insulin receptor α-subunit in many cells, causing IR [7,34,35]. Consequently, ENPP1 has being associated with impaired glucose metabolism. Subjects with IR have high concentrations of ENPP1 protein [7,36,37,38,39]. Accordingly, transgenic mice overexpressing ENPP1 in skeletal muscles and liver showed elevated glucose and insulin concentrations as well as decreased glucose uptake in muscle [40]. In contrast, the total knockdown of ENPP1 gene in the mice liver was able to decrease both postprandial and fasting plasma glucose levels [7,41].

Thus, taking into account the role of ENPP1 in IR, several studies have investigated the association between the ENPP1 K121Q polymorphism and IR or T2DM (reviewed in [7]). To this date, eight meta-analyses had reported that ENPP1 121Q allele carriers in different populations and ethnicities are at increased risk of developing T2DM [11,42,43,44,45,46,47,48]. In contrast, meta-analyses performed by Zhao et al. [49] and Weedon et al. [50] did not find such an association with T2DM in Europeans.

Regarding the association between the K121Q polymorphism and DKD or related features, De Cosmo et al. [51] showed that this variant influences GFR decline in proteinuric type 1 diabetic patients: GFR decreased earlier in subjects with QQ/KQ genotypes compared to subjects with KK genotype. We previously demonstrated that the Q variant was associated with ESRD
in type 1 diabetic patients and short DM duration [18]. Q allele carriers (KQ/ QQ) had a two fold increased risk of developing ESRD when compared to patients with KK genotype (OR 2.3; 95% CI 1.2–4.6) [18]. Moreover, De Cosmo et al. [20] reported that Italian T2DM patients with the Q allele had an increased risk of having a decreased GFR as well as more severe DKD than non-carriers. This is in accordance with data reported by Lin et al. [21] and Wu et al. [19], who also described an association between the Q allele and increased risk of DKD in Asian patients with T2DM. Nevertheless, other studies did not observe any association between the K121Q polymorphism and DKD or related features [7,10,23,32]. This might be due to an effect of ethnicity on this association. The present meta-analysis suggests that the Q allele is significantly associated with DKD in both Europeans and Asians, possibly under an additive inheritance model. There was only one [10] study that included African descent subjects. Therefore, the role of this polymorphism in these subjects remains to be determined. Taking into account the small number of studies carried out in each ethnicity, additional studies with larger sample sizes are still needed to confirm the association between the K121Q variant and DKD in different ethnicities.

It is worth noting that several genome wide association studies have searched for chromosomal regions linked or associated with renal function phenotypes in T2DM patients, such as DKD, eGFR or creatinine/albumin ration [52,53,54,55,56,57,58,59,60,61]. The ENPP1 gene is located in the 6q22.q23 region (http://www.ncbi.nlm.nih.gov/gene). Therefore, although some studies reported associations between polymorphic markers on chromosome 6q with DKD phenotypes [53,56,59], the reported closest region to 6q22-q23 was an association of a marker on 6q22.31 with survival on dialysis rates in African-Americans T2DM patients [61]. Moreover, Mooyaart et al. [62] performed a meta-analysis to assess the pooled effects of several genetic variants that have reproducibly been associated with DKD in previous studies. Their search identified 34 replicated genetic variants and, of these, 21 remained associated with DKD in the meta-analysis. Importantly, the K121Q polymorphism was not included among the 34 identified genetic variants since the results regarding this polymorphism were not constantly replicated in different populations.

The specific mechanisms that explain the association between the Q allele and risk for DKD are not known [7]. However, it is biological plausible that ENPP1 has a role in kidney tissue injury since it is acknowledged that ENPP1 gene is expressed in both kidney mesangial and endothelial cells [63], and these cells show progressive pathological changes during the progression from normoalbuminury to overt DKD [7,18]. The Q allele interacts more strongly with the insulin receptor than the K allele, decreasing the autophosphorylation of this receptor [12]. The Q allele carriers seem to exhibit worse IR and hyperinsulinemia than subjects with the KK genotype [64]. Hyperinsulinemia might increase sodium resorption in the kidneys, causing augmented sympathetic-adrenergic activity, volume expansion, and increased expression of the angiotensin type II receptor, impairing peripheral vasodilatation [65]. Reduced vasodilatation as well as increase volume might predispose to arterial hypertension, a well known risk factor for DKD [7,65,66].

Meta-analysis has been regarded as a powerful tool for pooling data from several studies, which could overcome the problem of small sample numbers as well as insufficient statistical power of genetic association studies of complex diseases [26]. Of note, the present meta-analysis had an 80% power (α = 0.05) to detect an OR ≥ 1.35. Nevertheless, the results of the present meta-analysis should be interpreted within the context of a few limitations. Meta-analyses can be prone to publication bias, and although we made every effort to find unpublished results, we cannot be sure if small negative studies were overlooked. One of the studies identified [23] was not included in our meta-analysis because its control group was constituted of healthy subjects without DKD, and our inclusion criteria were restricted to studies that comprised control...
subjects with DM but without any degree of DKD. Keene et al. [23] did not observe any association between the K121Q polymorphism and ESRD in T2DM patients from an African-American population. In addition, heterogeneity could be a significant problem when interpreting the findings of any meta-analysis. In short, within these limitations, our data seem to be robust, since we did not detect any significant inter-study heterogeneity in any of the genetic inheritance models analyzed.

In conclusion, our results indicate that the \textit{ENPP1} K121Q polymorphism is associated with risk of DKD in European and Asian populations. Since only small sample sizes could be obtained for analyses stratified by ethnicity, further studies with larger sample sizes are needed to confirm the effect possibly played by \textit{ENPP1} in the pathogenesis of DKD and related features.

**Supporting Information**

S1 PRISMA Checklist. (DOC)

S1 Table. Meta-analysis on genetic association studies checklist. (DOCX)

S2 Table. Characteristics of the studies included in the meta-analysis. Legend: NA: not evaluated. DKD: Diabetic Kidney Disease. 1: Urinary albumin excretion (UAE) (mg/24h): 796 (16-14545). 2: Albumin Creatinine Ratio (ACR): 250 mg/g (men) or 355 mg/g (women). 3: Microalbuminuria: UAE 20–199 μg/min or Proteinuria: UAE ≥200 μg/min. 4: Microalbuminuria: UAE 20–199 μg/min or Proteinuria: UAE ≥200 μg/min. 5: Positive dipstick test for protein; Macroalbuminuria: two tests of spot urinary albumin >300 mg/mg of creatinine. 6: ACR >300 μg/mg; Blood Urea Nitrogen >20 mg/dl or Creatinine >1.7 mg/dl. (DOC)

S3 Table. Genotype and allele distributions of the \textit{ENPP1} K121Q polymorphism in patients with diabetic kidney disease and control subjects. Legend: \(^a\) African descendants; \(^b\) European descendants. (DOC)

**Author Contributions**

Conceived and designed the experiments: DAS BMS TSA DC. Performed the experiments: DAS MPB BMS BBN AS TSA. Analyzed the data: DAS BMS AS TSA DC. Contributed reagents/materials/analysis tools: LHC. Wrote the paper: DAS BBN DC LHC.

**References**

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011; 94: 311–321. doi: 10.1016/j.diabres.2011.10.029 PMID: 22079683

2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009; 32: 62.

3. Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013; 2013: 248563. doi: 10.1155/2013/248563 PMID: 23862164

4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013; Suppl: S1-S150.
5. Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014; 63: S39–62. doi: 10.1053/j.ajkd.2013.10.048 PMID: 24461729

6. Carpena MP, Rados DV, Sortica DA, Souza BM, Reis AF, Canani LH et al. Genetics of diabetic nephropathy. Arq Bras Endocrinol Metabol. 2010; 54: 253–261. PMID: 20520954

7. Sortica DA, Crispim D, Zaffari GP, Friedman R, Canani LH. The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy. Arq Bras Endocrinol Metabol. 2011; 55: 677–685. PMID: 22231969

8. Thomas MC, Groop PH, Tryggvason K. Towards understanding the inherited susceptibility for nephropathy in diabetes. Curr Opin Nephrol Hypertens. 2012; 21: 195–202. doi: 10.1097/MNH.0b013e328350313e PMID: 22314557

9. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007; 2: 1306–1316. PMID: 17942768

10. Leitao CB, Nabinger GB, Krahe AL, Bolson PB, Gerchman F, Gross JL, et al. The role of K121Q ENPP1 polymorphism in diabetes mellitus and its complications. Braz J Med Biol Res. 2008; 41: 229–234. PMID: 18176722

11. Bacci S, Ludovico O, Prudente S, Zhang YY, Di Paola R, Mangiacotti D, et al. The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction. Diabetes. 2005; 54: 3021–3025. PMID: 16186408

12. Pizzuti A, Frittitta L, Argiolas A, Baratta R, Goldfine ID, Bozzali M, et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes. 1999; 48: 1881–1884. PMID: 10480624

13. Meyre D, Bouatia-Naji N, Tounian A, Samson C, Lecoeur C, Vatin V, et al. Variants of ENPP1 are associated with childhood and adult obesity and increasing the risk of glucose intolerance and type 2 diabetes. Nat Genet. 2005; 37: 863–867. PMID: 16025115

14. Palmer ND, Freedman BI. Insights into the genetic architecture of diabetic nephropathy. Curr Diab Rep. 2012; 12: 423–431. doi: 10.1007/s11892-012-0279-2 PMID: 22573336

15. De Cosmo S, Menzaghi C, Prudente S, Trischitta V. Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence. Nephrol Dial Transplant. 2013; 28: 29–36. doi: 10.1093/ndt/gfs290 PMID: 23048172

16. Buckley MF, Loveland KA, McKinstry WJ, Garson OM, Goding JW. Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem. 1990; 265: 17506–17511. PMID: 2211644

17. Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol. 2000; 35: 393–432. PMID: 11202013

18. Canani LH, Ng DP, Smiles A, Rogus JJ, Warram JH, Krolewski AS. Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1) and early development of advanced diabetic nephropathy in type 1 diabetes. Diabetes. 2002; 51: 1188–1193. PMID: 11916943

19. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009; 24: 3360–3366. doi: 10.1093/ndt/gfp271 PMID: 19506043

20. De Cosmo S, Minenna A, Zhang YY, Thompson R, Miscio G, Vedovato M, et al. Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with decreased kidney function among patients with type 2 diabetes. Am J Kidney Dis. 2009; 53: 273–280. doi: 10.1053/j.ajkd.2008.07.040 PMID: 18950909

21. Lin CC, Wu CT, Wu LS. Ectonucleotide pyrophosphatase/phosphodiesterase 1 K173Q polymorphism is associated with diabetic nephropathy in the Taiwanese population. Genet Test Mol Biomarkers. 2011; 15: 239–242. doi: 10.1089/gtmb.2010.0148 PMID: 21198320

22. Jacobsen P, Grarup N, Tarnow L, Parving HH, Pedersen O. Polymorphism in the ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1) has no impact on progression of diabetic nephropathy in type 1 diabetic patients. Nephrol Dial Transplant. 2002; 17: 1408–1412. PMID: 12147787

23. Keene KL, Mychaleckyj JC, Smith SG, Leak TS, Perlegas PS, Langefeld CD, et al. Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes. 2008; 57: 1057–1062. doi: 10.2337/db07-0886 PMID: 18184924

24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264–269, W264. PMID: 19622511
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008–2012. PMID: 10789670

26. de Souza BM, Brondani LA, Boucas AP, Sortica DA, Kramer CK, Canani LH, et al. Associations between UCP1–3826A/G, UCP2–666G/A, AliA55Val and Ins/Del, and UCP3–55C/T polymorphisms and susceptibility to type 2 diabetes mellitus: case-control study and meta-analysis. 2013; PLoS One 8: e54259. doi: 10.1371/journal.pone.0054259 PMID: 23365654

27. Brondani LA, Assmann TS, de Souza BM, Boucas AP, Canani LH, Crispim D. Meta-Analysis Reveals the Association of Common Variants in the Uncoupling Protein (UCP) 1–3 Genes with Body Mass Index Variability. PLoS One. 2014; 9: e96411. doi: 10.1371/journal.pone.0096411 PMID: 24804925

28. Boucas AP, Brondani LA, Souza BM, Lemos NE, de Oliveira FS, Canani LH, et al. The A allele of the rs1990760 polymorphism in the IFIH1 gene is associated with protection for arterial hypertension in type 1 diabetic patients and with expression of this gene in human mononuclear cells. PLoS One. 2013; 8: e83451. doi: 10.1371/journal.pone.0083451 PMID: 24368202

29. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603–605. doi: 10.1007/s10654-010-9491-z PMID: 20652370

30. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attila J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005; 34: 1319–1328. PMID: 16115824

31. Higgins JP, Spiegelhalter DJ. Being sceptical about meta-analyses: a Bayesian perspective on magnesiuim trials in myocardial infarction. Int J Epidemiol. 2002; 31: 96–104. PMID: 11914302

32. Tarnow L, Grarup N, Hansen T, Parving HH, Pedersen O. Diabetic microvascular complications are not associated with two polymorphisms in the GLUT-1 and PC-1 genes regulating glucose metabolism in Caucasian type 1 diabetic patients. Nephrol Dial Transplant. 2001; 16: 1653–1656. PMID: 11477169

33. Keshavarz P, Inoue H, Sakamoto Y, Kunika K, Tanahashi T, Nakamura N, et al. No evidence for association of the ENPP1 (PC-1) K121Q variant with risk of type 2 diabetes in a Japanese population. J Hum Genet. 2006; 51: 559–566. PMID: 16607460

34. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature. 1995; 373: 448–451. PMID: 7830796

35. Maddux BA, Goldfine ID. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes. 2000; 49: 13–19. PMID: 10615944

36. Frittitta L, Youngren JF, Sbraccia P, D’Adamo M, Buongiorno A, Vigneri R, et al. Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia. 1997; 40: 282–289. PMID: 9084965

37. Frittitta L, Youngren J, Vigneri R, Maddux BA, Trischitta V, Goldfine ID. PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia. 1996; 39: 1190–1195. PMID: 8897006

38. Youngren JF, Maddux BA, Sasson S, Sbraccia P, Tapsco ME, Swanson MS, et al. Skeletal muscle content of membrane glycoprotein PC-1 in obesity. Relationship to muscle glucose transport. Diabetes. 1996; 45: 1324–1328. PMID: 8926966

39. Frittitta L, Spampinato D, Solini A, Nosadini R, Goldfine ID, Vigneri R, et al. Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes. 1998; 47: 1095–1100. PMID: 9648833

40. Maddux BA, Chang YN, Accili D, McGuinness OP, Youngren JF, Goldfine ID. Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia. Am J Physiol Endocriol Metab. 2006; 290: E746–749. PMID: 16278247

41. Zhou HH, Chin CN, Wu M, Ni W, Quan S, Liu F, et al. Suppression of PC-1/ENPP1 expression improves insulin sensitivity in vitro and in vivo. Eur J Pharmacol. 2009; 616: 346–352. doi: 10.1016/j.ejphar.2009.06.057 PMID: 19577557

42. Abate N, Chandalia M, Satija P, Adams-Huet B, Grundy SM, Sandeep S, et al. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes. 2005; 54: 1207–1213. PMID: 15733263

43. Grarup N, Urhammer SA, Ek J, Albrechtsen A, Glumer C, Borch-Johnsen K, et al. Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. Diabetologia. 2006; 49: 2097–2104. PMID: 16985358
44. Berhouma R, Koidhi S, Ammar M, Abid H, Baroudi T, Baroudi T, et al. Genetic susceptibility to type 2 diabetes: a global meta-analysis studying the genetic differences in Tunisian populations. Hum Biol. 2012; 84: 423–435. doi: 10.3378/027.084.0405 PMID: 23249316

45. Jing C, Xueyao H, Linong J. Meta-analysis of association studies between five candidate genes and type 2 diabetes in Chinese Han population. Endocrine. 2012; 42: 307–320. PMID: 22391941

46. Li YY. ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11,855 subjects. Metabolism. 2012; 61: 625–633. doi: 10.1016/j.metabol.2011.10.002 PMID: 22136912

47. McAteer JB, Prudente S, Bacci S, Lyon HN, Hirschhorn JN, Trischitta V, et al. The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes. 2012; 57: 1125–1130.

48. Wang M, Peng C, QuYL, Huang QY. [Association and meta-analysis of ENPP1 K121Q with type 2 diabetes in Han Chinese.]. Yi Chuan. 2010; 32: 808–816. PMID: 20709678

49. Zhao T, Liu Z, Zhang D, Liu Y, Yang Y, Zhou D, et al. The ENPP1 K121Q polymorphism is not associated with type 2 diabetes or obesity in the Chinese Han population. J Hum Genet. 2011; 56: 12–16. doi: 10.1038/jhg.2010.124 PMID: 20981035

50. Weedon MN, Shields B, Hitman G, Walker M, McCarthy MI, Hattersley AT, et al. No evidence of association of ENPP1 variants with type 2 diabetes or obesity in a study of 8,089 U.K. Caucasians. Diabetes. 2006; 55: 3175–3179. PMID: 17065358

51. De Cosmo S, Argiolas A, Miscio G, Thomas S, Piras GP, Trevisan R, et al. A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria. Diabetes. 2000; 49: 521–524. PMID: 10868979

52. Arar NH, Voruganti VS, Nath SD, Thameem F, Bauer R, Cole SA, et al. A genome-wide search for linkage to chronic kidney disease in a community-based sample: the SAFHS. Nephrol Dial Transplant. 2008; 23: 3184–3191. doi: 10.1093/ndt/gfn215 PMID: 18443212

53. Craig DW, Millis MP, DiStefano JK. Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to Type 1 diabetes. Diabet Med. 2009; 26: 1090–1098. doi: 10.1111/j.1464-5491.2009.02846.x PMID: 19929986

54. Freedman BI, Bowden DW, Rich SS, Valis MM, Hicks PJ, et al. A genome scan for all-cause end-stage renal disease in African Americans. Nephrol Dial Transplant. 2005; 20: 712–718. PMID: 15701670

55. Krolewski AS, Poznik GD, Placha G, Canani L, Dunn J, Walker W, et al. A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int. 2006; 69: 129–136. PMID: 16374433

56. Schelling JR, Abboud HE, Nicholas SB, Pahl MV, Sedor JR, Adler SG, et al. Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephropathy and Diabetes (FINDB). Diabetes. 2008; 57: 2519–2526. doi: 10.2337/db07-1086 PMID: 18559660

57. Mooyaart AL, Valk EJ, van Es LA, Bruijn JA, de Heer E, Freedman BI, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia. 2011; 54: 544–553. doi: 10.1007/s00125-010-1996-1 PMID: 21127830

58. Goding JW, Howard MC. Ecto-enzymes of lymphoid cells. Immunol Rev. 1998; 161: 5–10. PMID: 9601561
64. Gu HF, Almgren P, Lindholm E, Frittitta L, Pizzuti A, Trischitta V, et al. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis. Diabetes. 2000; 49: 1601–1603. PMID: 10969847

65. Abate N. Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J Diabetes Complications. 2000; 14: 154–174. PMID: 10989324

66. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001; 86: 713–718. PMID: 11158035